Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Correction to: FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children’s Oncology Group trial AALL0631

The Original Article was published on 23 February 2021

Correction to: Leukemia

https://doi.org/10.1038/s41375-021-01177-6

Figure 3 of the original article was an incorrect version. The correct figure is:

figure3

Fig. 3

The original article has been updated.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Patrick A. Brown.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Brown, P.A., Kairalla, J.A., Hilden, J.M. et al. Correction to: FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children’s Oncology Group trial AALL0631. Leukemia 35, 1527 (2021). https://doi.org/10.1038/s41375-021-01245-x

Download citation

Search

Quick links